Optically Active 2-Amino-Phosphonoalkanoic Acid Salt Crystallization
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Nahlsgen, a gamma-glutamyl transpeptidase inhibitor, is unstable in its oily form at room temperature and decomposes easily, making it difficult to store and handle.
Innovation Solution
The development of optically active 2-amino-phosphonoalkanoic acid salts and their hydrates, which are produced by reacting DL-2-amino-phosphonoalkanoic acid with an optically active basic compound, resulting in diastereomeric salts with excellent crystallinity and improved storage stability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If Nahlsgen is stored at room temperature, then it is easy to handle, but it decomposes easily and has poor storage stability
Solution Approach 1:
The invention changes the physical state parameter of the compound from oily to crystalline by forming a salt with an optically active basic compound. This parameter change enables the substance to be stored at room temperature without decomposition, resolving the contradiction between ease of handling and storage stability.
Solution Approach 2:
The invention creates a composite salt structure by combining the optically active 2-amino-phosphonoalkanoic acid with an optically active basic compound. This composite material exhibits both crystallinity for stable storage and the desired pharmacological properties, maintaining ease of operation while improving reliability.
2Reliability
If Nahlsgen is stored in refrigerated or frozen conditions, then storage stability is improved, but it becomes difficult to handle
Solution Approach 1:
By transforming the compound into a crystalline salt form, the invention raises the storage temperature parameter from refrigerated/frozen to room temperature. This parameter change simultaneously improves both storage stability and ease of handling, eliminating the need for cold storage conditions.
3Reliability
If DL-2-amino-phosphonoalkanoic acid is used as a racemate, then pharmacological activity is achieved, but optical isomers cannot be efficiently isolated
Solution Approach 1:
The invention introduces an optically active basic compound as an intermediary substance to resolve the racemate into diastereomeric salts. This intermediary enables efficient separation of optical isomers through fractional crystallization, while the desired isomer can be recovered to maintain pharmacological activity.
Solution Approach 2:
The invention segments the racemic mixture into separate diastereomeric salt components through salt formation. This segmentation allows for efficient isolation of individual optical isomers by exploiting the different crystallization properties of the diastereomeric salts, improving manufacturing efficiency while preserving pharmacological activity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The resulting compounds have pharmacological activities comparable to Nahlsgen, including collagen production promotion, glutathione production, and wound healing, while offering superior storage stability and ease of handling.
Implementation Method 1
reacting DL-2-amino-phosphonoalkanoic acid with an optically active basic compound, to give a diastereomeric salt mixture
Implementation Method 2
subjecting the diastereomeric salt mixture to fractional crystallization to isolate one of the first and second diastereomeric salts
Data Source
AI summary
A novel compound has pharmacological activities comparable to those of Nahlsgen and is storable excellently stably. The compound can be produced by a method according to the present invention for producing an optically active 2-amino-phosphonoalkanoic acid salt. In the method, a starting material DL-2-amino-phosphonoalkanoic acid represented by Formula (1) or a hydrate thereof is reacted with an optically active basic compound other than an optically active lysine, to give a diastereomeric salt mixture including a first salt (including a hydrate salt) between a D-2-amino-phosphonoalkanoic acid represented by Formula (1-1) and the optically active basic compound, and a second salt (including a hydrate salt) between an L-2-amino-phosphonoalkanoic acid represented by Formula (1-2) and the optically active basic compound. The diastereomeric salt mixture is fractionally crystallized to isolate one of the first and second diastereomeric salts.